FDA creates ‘green list’ of GLP-1 drug ingredients approved for entry in the U.S.
by Tina Brown edited by Sadie Harley, reviewed by Andrew Zinin The U.S. Food and Drug Administration has created a “green list” import alert to stop unapproved and unverified glucagon-like peptide 1 (GLP-1) drug ingredients from entering the United States. Due to shortages of the FDA-approved GLP-1 drugs, like semaglutide and tirzepatide, which are used for […]
FDA creates ‘green list’ of GLP-1 drug ingredients approved for entry in the U.S. Read More »
